Business Context and Reporting Period
Company: Xencor, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2014
Event: Termination of a Material Definitive Agreement with Amgen Inc.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
- Termination of Agreement: Xencor and Amgen terminated their Collaboration and Option Agreement dated December 22, 2010, effective October 27, 2014.
- Asset Reacquisition: Xencor reacquired all worldwide rights to the asset XmAb5871.
- Financial Impact: The Company did not incur any early termination penalty.
- Future Rights: Amgen was granted a right of first negotiation for an exclusive license to develop and commercialize XmAb5871. This right expires on the earlier of: (i) the start of a Phase 3 trial with XmAb5871, (ii) five years from the termination date, or (iii) the acquisition of Xencor.
Outlook, Risks, and Management Commentary
- Strategic Shift: Xencor now retains full control over XmAb5871 but must negotiate with Amgen first if seeking a third-party partner.
- Contingency: If no agreement is reached with a third party within twelve months, Amgen's right of first negotiation is revived.
- Previous Obligations: Under the original agreement, Xencor was required to lead research and development until Amgen exercised its option following a Phase 2b trial in rheumatoid arthritis subjects.
Investor Verification Checklist
- Verify the status of the Phase 2b proof-of-concept clinical trial for XmAb5871 in rheumatoid arthritis.
- Confirm whether Xencor intends to seek a new licensee or partner for XmAb5871, triggering Amgen's right of first negotiation.
- Review the press release (Exhibit 99.1) for additional details on the strategic rationale for the termination.
- Monitor future filings for any new licensing agreements involving XmAb5871.